PATENT COOPERATION TREATY

REC'D	30	AUG	2005	
			PCT	
WIPO			M.C.1	Ė

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

	(PCT Article 36 and	d Rule 70)	
Applicant's or agent's file reference 501872 KXR	FOR FURTHER ACTIO	ON	See Form PCT/IPEA/416
International application No. PCT/NZ2004/000222	International filing date (a 20 September 2004	day/month/year)	Priority date (day/month/year) 18 September 2003
International Patent Classification (IPC) or	national classification and	IPC	
Int. Cl. 7 G01N 21/05, 33/577			
Applicant THE HORTICULTURE AND F	FOOD RESEARCH INS	TITUTE OF NEW	ZEALANDLIMITED
This report is the international prelimin Authority under Article 35 and transmi	nary examination report, estitted to the applicant accord	tablished by this Int ling to Article 36.	ernational Preliminary Examining
2. This REPORT consists of a total of 5			
3. This report is also accompanied by AN			
a. X (sent to the applicant and to the	he International Bureau) a	total of 2 sheets,	as follows:
sheets containing rectific Administrative Instruction Sheets which supersede the disclosure in the into Box. b. (sent to the International Burna sequence listing and/or table Relating to Sequence Listing	cations authorized by this A ons). earlier sheets, but which the ernational application as file reau only) a total of (indicate le related thereto, in compute (see Section 802 of the Ad	is Authority considered, as indicated in it te type and number ter readable form or luministrative Instruc	ny, as malouted in the large
4. This report contains indications relat	ting to the following items:		
X Box No. I Basis of the re	port		•
Box No. II Priority Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability			
Box No. IV Lack of unity of invention			
citations and e	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement		
X Box No. VI Certain docur			
	vations on the international	application	
Date of submission of the demand 18 July 2005		Date of completion 16 August 2005	of the report
Name and mailing address of the IPEA/AU	·	Authorized Officer	
AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUS' E-mail address: pct@ipaustralia.gov.au	•	ROSS OSBORI Telephone No. (0)	

1375

International application No.

PCT/NZ2004/000222

Box	x No. I Basis of the report	\dashv
1.	With regard to the language, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.	
	This report is based on translations from the original language into the following language which is the language of a translation furnished for the purposes of:	
	international search (under Rules 12.3 and 23.1 (b))	
	publication of the international application (under Rule 12.4)	
	international preliminary examination (under Rules 55.2 and/or 55.3)	
2.	With regard to the elements of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report): the international application as originally filed/furnished	
	X the description:	
	pages 1-47, 52 as originally filed/furnished	
	pages* received by this Authority on with the letter of pages* received by this Authority on with the letter of	
	pages* received by this Authority on with the letter of X the claims:	
	pages 48, 50, as originally filed/furnished	
	pages* as amended (together with any statement) under Article 19	
	pages* 49, 51 received by this Authority on 18 July 2005 with the letter of 18 July 2005	
	pages* received by this Authority on with the letter of	
	X the drawings: pages 1/7-7/7 as originally filed/furnished	
	pages* received by this Authority on with the letter of	
	pages* received by this Authority on with the letter of	
	a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.	
3.	The amendments have resulted in the cancellation of:	
	the description, pages	
	the claims, Nos.	l
	the drawings, sheets/figs	
1	the sequence listing (specify):	
	any table(s) related to the sequence listing (specify):	
4.	This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Ru 70.2(c)).	le
	the description, pages	
	the claims, Nos.	
	the drawings, sheets/figs	
	the sequence listing (specify):	•
	any table(s) related to the sequence listing (specify):	
*	* If item 4 applies, some or all of those sheets may be marked "superseded."	

International application No. PCT/NZ2004/000222

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1.	Statement		<i>:</i>
	Novelty (N)	Claims 1-18	YES
		Claims	NO
	Inventive step (IS)	Claims 1-18	YES
	, 11	Claims	NO
	Industrial applicability (IA)	Claims 1-18	YES
	modular approved.	Claims	. NO

2. Citations and explanations (Rule 70.7)

D1 US6342349

D2 Wu Y. et al,

NOVELTY(N), INVENTIVE STEP (IS) Claims 1-18

D1 discloses an assay device that can be used with competitive binding assays that features 'dual linkers' with examples of a binding partner bound to a solid metal surface by means of a linker and in the liquid phase a binding partner bound through a linker to a optical signaller particle for the detection of analyte. D2 discloses the use of nanoparticles and linkers of optimized length to attach to binding partners for improved sensitivity in a flow through surface plasmon resonance-based immunoassay.

None of the prior art documents disclose an flow through immunoassay for the detection of haptens featuring an analyte/antibody bound through a linker to a high mass signalling molecule and a antibody/analyte bound to a sensor through a second linker. D2 does disclose the use of a signalling particle but the signal is an optical one. The claims are therefore novel.

The applicant's arguments that it would not be obvious to combine the teaching of D1 which is a non-flow through assay which may utilise multiple linkers with the teaching of D2 which is a flow through system that utilises only one linker are accepted. All claims therefore have an inventive step.

International application No.

PCT/NZ2004/000222

Box No. VI	Certain	documents	cited

1. Certain published documents (Rule 70.10)

Application No.
Patent No.
WO 2004/042403

Publication date (day/month/year)

21 May 2004

Filing date
(day/month/year)

3 November 2003

Priority date (valid claim)
(day/month/year)

4 November 2002

WO 2004/042403 discloses a plasmon resonance immunoassay which uses immunogold and a solid phase with attached substrate binding antibodies but does not disclose the use of dual linkers.

2. Non-written disclosures (Rule 70.9)

Kind of non-written disclosure

Date of non-written disclosure (day/month/year)

Date of written disclosure referring to non-written disclosure (day/month/year)

International application No. PCT/NZ2004/000222

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

The claims are not concise, there are 6 independent claims among the 18 claims that define the invention. There does not appear to be six different substantively described variations of the invention in the description and these claims do not appear to differ in any fundamental manner. This lack of conciseness also leads to a lack of clarity about the precise ambit of the invention and matter should be addressed by reducing the number of independent claims.

The description only supports flow though assays where the signalling is done on the basis of mass, such as plasmon resonance assays and all the claims should be clearly limited to this type of assay. Otherwise some of the claims arguably cover dual linker assays such those described in D1 where there is a 'high mass' particle that signals on the basis of its optical properties and the options envisaged for the assays appear to include options where the sample flows through or over the detection sites.